Patent search ap:("NOVARTIS AG") AND inv:"Barbara Brannetti" Page 3

21.

发明授权
Antibodies that bind factor P 有权
Title translation: 结合因子P的抗体

公开(公告)号：US09051365B2

公开(公告)日：2015-06-09

申请号：US13716526

申请日：2012-12-17

Applicant: NOVARTIS AG

Inventor： Leslie Ngozi Anuna Johnson , Ute Jaeger , Yong-In Kim , Christian Carsten Silvester Kunz , Igor Splawski , Michael Roguska , Joy Ghosh , Barbara Brannetti , Sha-Mei Liao , Michael Stefanidakis

IPC: A61K39/395 , C07K16/28 , C07K16/18 , G01N33/68 , C07K16/24 , A61K39/00

CPC classification number: C07K16/18 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/24 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/40 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/6863

Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).

Abstract translation: 本发明涉及结合补体因子P并用于其的抗体或其抗原结合片段，以及抗因子P抗体与结合补体成分5（C5）的抗体或其抗原结合片段的组合。

22.

发明申请
NUCLEIC ACID MOLECULES ENCODING CHIMERIC ANTIGEN RECEPTORS COMPRISING A CD20 BINDING DOMAIN 有权

公开(公告)号：US20220387486A1

公开(公告)日：2022-12-08

申请号：US17246351

申请日：2021-04-30

Applicant: Novartis AG , The Trustees of the University of Pennsylvania

Inventor： Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Walter Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Patricia Pinto Guimaraes , Saar Gill , Marco Ruella , Regina M. Young

IPC: A61K35/17 , C07K16/28 , A61P35/00 , A61K38/17 , C12N15/85

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

23.

发明申请
METHOD OF DETECTING TIM-3 USING ANTIBODY MOLECULES TO TIM-3 有权

公开(公告)号：US20220185883A1

公开(公告)日：2022-06-16

申请号：US17484794

申请日：2021-09-24

Applicant: Novartis AG , DANA-FARBER CANCER INSTITUTE, INC. , The Children's Medical Center Corporation

Inventor： Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu

IPC: C07K16/28 , G01N33/574 , A61K39/395 , A61K45/06 , G01N33/68

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

24.

发明申请
COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 有权

公开(公告)号：US20220133889A1

公开(公告)日：2022-05-05

申请号：US17478370

申请日：2021-09-17

Applicant: Novartis AG , DANA-FARBER CANCER INSTITUTE, INC. , The Children's Medical Center Corporation

Inventor： Glenn Dranoff , Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu

IPC: A61K39/395 , A61K39/00 , C07K16/28 , A61P35/00 , A61K45/06

Abstract: Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.

25.

发明授权
Method of detecting TIM-3 using antibody molecules to TIM-3 有权

公开(公告)号：US11155620B2

公开(公告)日：2021-10-26

申请号：US16588063

申请日：2019-09-30

Applicant: Novartis AG , DANA-FARBER CANCER INSTITUTE, INC. , Children's Medical Center Corporation

Inventor： Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu

IPC: C07K16/28 , G01N33/574 , A61K39/395 , A61K45/06 , G01N33/68

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

26.

发明授权
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell 有权

公开(公告)号：US11149076B2

公开(公告)日：2021-10-19

申请号：US16256731

申请日：2019-01-24

Applicant: Novartis AG , The Trustees of the University of Pennsylvania

Inventor： Hans Bitter , Jennifer Mary Bordeaux , Barbara Brannetti , Jennifer Brogdon , Naveen Kumar Dakappagari , Saar Gill , Steven Highfill , Lu Huang , Carl H. June , Ju Young Kim , Ming Lei , Na Li , Andreas Loew , Elena Orlando , Marco Ruella , Thai Tran , Jimin Zhang , Li Zhou

IPC: C07K14/705 , C07K14/725 , C07K16/28 , A61K45/06 , A61K39/00 , A61K38/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

27.

发明申请
ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF 审中-公开

公开(公告)号：US20200308277A1

公开(公告)日：2020-10-01

申请号：US16841029

申请日：2020-04-06

Applicant: Novartis AG , DANA-FARBER CANCER INSTITUTE, INC. , The Children's Medical Center Corporation

Inventor： Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu

IPC: C07K16/28 , A61K39/395 , G01N33/68 , G01N33/574 , A61K45/06

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

28.

发明授权
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain 有权

公开(公告)号：US10525083B2

公开(公告)日：2020-01-07

申请号：US15727402

申请日：2017-10-06

Applicant: Novartis AG , The Trustees of the University of Pennsylvania

Inventor： Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Guimaraes

IPC: A61K35/17 , A61P35/00 , A61K38/17 , C12N15/85 , C07K16/28 , A61K39/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.